# Replidyne

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/replidyne

- Industry: Biotechnology
- Headquarters: St. Paul, US
- Website: www.replidyne.com
- Total disclosed funding: $103M
- Latest round: Series D (Sep 1, 2005)
- Investors on record: 8

## About

Founded in 2000.Replidyne is a privately held biopharmaceutical company focused on the discovery and development of new anti-infective drugs.

## Funding rounds

- Series D, Sep 1, 2005, $63M — HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, TPG, Temasek Holdings, Perseus, Quintiles EDP, Duquesne Capital Management
- Series B, Aug 17, 2004, $40M — HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, TPG, Perseus

## Investors

- HealthCare Ventures — Series B, Series D
- Morgenthaler Ventures (https://capitalatlas.ai/funds/morgenthaler-ventures) — Series B, Series D
- Sequel Venture Partners (https://capitalatlas.ai/funds/sequel-venture-partners) — Series B, Series D
- TPG (https://capitalatlas.ai/funds/tpg) — Series B, Series D
- Perseus (https://capitalatlas.ai/funds/perseus) — Series B, Series D
- Temasek Holdings — Series D
- Quintiles EDP — Series D
- Duquesne Capital Management — Series D